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Introduction:Although antidepressants play a major role in the treatment of patients with
depression, it is unclear which specific antidepressants are more efficacious than others.
This study aims to analyze the relationship between several antidepressant substances
and the time to readmission as well as the probability of being in hospital in a given week
by using prescription data.
Methods: The database was health-insurance claim data from the new Federal States
in Germany. The analysis consisted of all patients with unipolar depression at their index
admission in 2007 (N =1803). Patients were followed up for 2 years after discharge from
index hospitalization. Statistical analyses were conducted by discrete-time hazards models
and general estimation equation models, accounting for various predictors.
Results:Of all prescribed antidepressant substances, sertraline was related to an increased
time to readmission by 37% and to a reduction in the probability of being in hospital in a
given week by 40%. However, it was prescribed to only about 5% of the patients.
Conclusion: In this study, only sertraline appeared to have clinical and economic advan-
tages. It is remarkable that just a minority of patients received sertraline in our study, thus
differing from the prescription pattern in the US.
Keywords: antidepressants, sertraline, depression, time to psychiatric readmission, probability of being in hospital,
time hazard models
INTRODUCTION
Besides psychotherapy and cognitive behavioral therapy, anti-
depressant medication is a common treatment in patients with
depression (1, 2) and recommended in clinical guidelines (3,
4). The treatment with antidepressants is reported to be effec-
tive when compared to placebos, at least in patients with acute
and moderate to severe depression (5). First generation anti-
depressants [tricyclic antidepressants (TCAs) and monoamine
oxidase inhibitors (MAOIs)] were the mainstays for pharma-
cological treatment of depressive disorders for many years (6,
7). In the past decades, several new drugs (second-generation
antidepressants) with improvements in safety and tolerability
have been introduced (7–9). They include selective serotonin
reuptake inhibitors (SSRIs; e.g., escitalopram, sertraline) and
serotonin–norepinephrine reuptake inhibitors (SNRIs; e.g., ven-
lafaxine, duloxetine). In the US and Europe, SSRIs are most fre-
quently prescribed (1, 9, 10). However, there are less prescriptions
of SSRIs in Germany compared to other European countries (10).
German studies also suggest a preference for other antidepressants
according to the German anatomical therapeutical chemical code
(ATC-index) (e.g., venlafaxine, mirtazapine) (11, 12) or for TCAs
(e.g., trimipramine) (13).
However, despite the general efficacy of antidepressants, up to
now it is not clear which single antidepressant drug is the obvious
first-line treatment of depression (9). Recent reviews have stated
that sertraline might be superior to its competitors with respect to
efficacy, acceptability, and tolerability (6, 14, 15) as well as acqui-
sition cost (15). Other studies argue in favor of escitalopram (16),
venlafaxine (17), or mirtazapine (18) or did not find any differ-
ence between second-generation antidepressants with respect to
efficacy (19–22).
Previous studies on antidepressants and outcome have mostly
used experimental trials in terms of head-to-head comparisons
(6, 22) or placebo-controlled studies (21, 22). However, natural-
istic studies allow for a higher ecological validity, fewer ethical
concerns, and less restriction on sample size as well as on observa-
tion period. To our knowledge, evidence is rare particularly with
respect to antidepressants and the long-term outcome measure
“time to readmission” (23, 24). Such studies give an insight into
the prevention of early readmission by appropriate treatment in
clinical practice. The time to readmission serves as a quality indi-
cator that might be lengthened by attending to stability of clinical
condition (25). To date, the most valid determinant of psychiatric
readmission is the number of previous admissions (26).
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Regarding the economical perspective, it is important to know
more about the relationship between antidepressants prescribed in
outpatient care and the probability of being in hospital in a given
time period. In general, findings on the cost-effectiveness of anti-
depressants are mixed (1). The main cost component in depressive
patients is inpatient care. In a recent German study, inpatient care
comprised 43.9% of the total annual direct costs of patients with
depression (27).
The aim of this study was to analyze the relationship between
first- and second-generation antidepressants in outpatient care
with respect to (a) the time until readmission and (b) the status of
“being in hospital at a given time period”in depressive patients. We
analyzed prescription data reflecting treatment under ecological
conditions and we controlled for several variables.
MATERIALS AND METHODS
STUDY DESIGN AND DATA SOURCE
This study is a retrospective analysis using electronic health-
insurance claims data from a German statutory health-insurance
company, located in the new Federal States (AOK Plus). The AOK
Plus covers about three million insured persons; the majority of
clients live in Saxony and Thuringia. We selected relevant informa-
tion out of several databases on depressive patients [a depressive
episode (F32, ICD-10) or a recurrent depressive disorder (F33,
ICD-10)]. The time span ranged from January 1, 2007 to Sep-
tember 30, 2010. Hospital data consisted of N = 71,490 inpatient
episodes due to a mental disorder (F-diagnosis by ICD-10) treated
in a psychiatric or psychosomatic unit. Further, we considered
data on prescribed drugs, diagnoses, episode-specific variables,
and personal characteristics (age, sex, residential region, type of
insurance, and period of coverage).
SAMPLE SELECTION
Figure 1 shows the process of sample reduction by specific selec-
tion criteria according to the research issue of our study: (a)
patients between 18 and 65 years; (b) at least one inpatient episode
with a disorder F32/F33; (c) at least one hospital admission in the
year 2007; (d) health-insured at least 95% of the time within the
observation period, referring to the health care system in Ger-
many; (e) adjusting database with respect to internal transfers and
data input errors; and (f) complete data in all predictor variables.
Steps (b) and (c) were conducted to select the index episode for
depressive patients. The observation period started with the dis-
charge from the index episode. Irrespective of the F-diagnosis in
the follow-up, we considered all readmissions of those patients
primarily diagnosed with a depressive disorder. Under clinical
considerations, we assumed that the basic symptomatology might
persist over 2 years and that, due to clinical comorbidity, diagnoses
might change over subsequent inpatient episodes.
Step (d) served to include only those patients who were health-
insured most of the time within the observation period of 2 years.
The aim was to obtain a sample that was comparable in terms of
the probability of returning to hospital. In Germany, not being
insured might be due to job transitions, lack of registration at the
employment office, or to changes of insurance company.
Step (e) was taken to improve data quality of the sample fulfill-
ing the inclusion criteria. We only considered data with complete
information on predictor variables. Of N = 1836 index episodes,
severity of illness was missing in 30 patients with unspecified
disorder (F32.8/F32.9; F33.8/F33.9). Employment status at index
admission was missing in three patients. The final sample consisted
of N = 1803 patients who had in total N = 1832 readmissions. Ten
patients experienced more than one readmission within the same
week. Accordingly, we only considered the last admission, which
finally resulted in N = 1822 readmissions.
PREDICTOR VARIABLES
Sociodemographic variables were gender (female vs. male), age (in
years), and employment status (employed vs. unemployed) in the
quarter of index admission.
Illness-related variables at the index episode were main diagno-
sis F32 vs. F33 (yes vs. no), severity of illness (mild to moderate vs.
severe), secondary diagnosis according to ICD-10 ((F0-F6; A0-E9,
G0-Z9), yes vs. no). For the final statistical models, we only consid-
ered secondary disorders prevalent in about 5% (at least 4.5%) of
the sample at the index episode (week= 0): at least one substance
use disorder, at least one anxiety disorder, at least one personality
disorder, at least one somatic/neurological disorder.
Time-varying predictor variables
Medication. We considered every prescription in outpatient care
of several types of drugs at weekly time intervals. Finally, we only
selected drugs that were taken by about 5% (at least 4.5%) of
the sample at the start of the observation period. The data finally
consisted of three different types of antidepressant according to
the ATC-index (11): non-selective monoamine-reuptake inhibitor
(NSMRI), SSRI, and others (not attributable to one of the pre-
vious groups). Further, we examined the following substances:
citalopram (SSRI), sertraline (SSRI), escitalopram (SSRI), trim-
ipramine (NSMRI), mirtazapine (others), venlafaxine (others),
and duloxetine (others).
Other drugs contained sedatives, psychotropic drugs other than
antidepressants (mostly antipsychotics), and drugs for all kinds
of somatic health problems. The number of defined daily doses
(DDD) (11) per medication package served as an estimate for the
duration of medication use.
With every new hospitalization episode, we used the corre-
sponding type of admission (emergency vs. regular, time-variant),
number of episode (logarithmized), length of previous admis-
sion in days (logarithmized) as predictors for the duration
until readmission. For the latter variables, we used the natural
logarithm.
STATISTICAL ANALYSIS
For each individual, we constructed a person–period dataset of
105 weekly time intervals, where we could easily set the time-
dependent predictor variables (28). We implemented two outcome
variables: (1) hospital admission yes (event= 1) vs. no (event= 0),
(2) status of hospital stay (in hospital, yes, event= 1 vs. out of
hospital, no, event= 0).
To analyze the first outcome “time to readmission,” we applied
extended survival models that are able to analyze more than one
event within the observation period. Therefore, the time indica-
tor was reset to zero after each hospitalization episode (29). Thus,
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FIGURE 1 | Sample selection process referring to inpatient episodes.
patients were assumed not to be at risk for a subsequent event until
the current event had terminated. As a result, we observed a min-
imum of 47 time intervals and a maximum of 105 time intervals
per patient. The person–period dataset for the first outcome finally
consisted of N = 181,049 observations and N = 1822 events.
To analyze the second outcome “being in hospital that week”
we considered all 105 time intervals per subject, thus the person–
period dataset for the second outcome was larger consisting of
N = 189,315 observations and N = 10,088 events.
For the time to readmission, we applied discrete-time hazard
models (28) allowing for a parsimonious representation of the
variable “time.” Thus, the models fit the shape of the logit-hazard
profile. The hazard probability describes the proportion of the risk
set that experiences the event during that period. To analyze the
probability of being in hospital, we applied a general estimation
equation (GEE) with binomial response for correlated data. We
used the natural logarithm (log) of time for all analyses.
We were interested in the question if antidepressants have an
additional contribution to sociodemographic, clinical, and further
medication variables on the outcome variables of interest. Accord-
ingly, we conducted three models for each outcome. First, we used
time and episode as predictors for the time to readmission, and
only time variables for the probability of being in hospital. Con-
cerning the latter, the number of previous inpatient episodes was
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not relevant. These models provide a standard against which later
models (including further predictors) can be compared (30). Sec-
ond, we added sociodemographic and clinical predictor variables
and finally all drug variables.
For the analyses, we used the genlin-procedure implemented
in SPSS 18. An independent working correlation matrix was esti-
mated by a subject variable (29) to account for multiple episodes
and their probable correlation within subjects. We used all med-
ication variables irrespective of the significance level. With respect
to the other probable predictors, the level of significance was set
to<0.01 in order to consider only the most important ones.
RESULTS
DESCRIPTIVE RESULTS
Of the N = 1803 patients, N = 779 (43%) had at least one read-
mission over the study period of 2 years. The maximum number
of readmissions per patient during the follow-up period was 22.
Table 1 summarizes the sample characteristics. The sample con-
sisted of almost twice as many female as male patients. The median
age was 48 years. Patients had a median length of stay of 34 days
with upper and lower quartiles of 53–18 days [=interquartile
range (IQR)]. Most of the patients had a depressive episode (F32).
About 50% of the patients were considered to be severely ill.
The most frequent secondary disorders were somatic/neurological
disorders as well as anxiety, personality, and substance use dis-
orders. Regular admissions were more frequent than emergency
admissions. About half of the patients (N = 934, 51.8%) received
antidepressant medication when considering only the substances
relevant for this study (see above). Most patients used antide-
pressants other than SSRIs or NSMRIs, especially the substances
mirtazapine (16.5%) and venlafaxine (16.3%). Only a minority
received sertraline (4.8%). Less than 10% used sedatives, whereas
more than one-third used other psychotropic drugs and almost
half of the patients used somatic medication.
DISCRETE-TIME HAZARDS MODEL: PREDICTORS OF TIME TO
READMISSION
As described above, we computed three statistical models when
analyzing the time to readmission by consecutively adding pre-
dictor variables (Table 2). First, we only considered the variable
time and number of episodes (readmissions). Second, we added
patient variables, mostly related to the index episode. Third, we
also examined several drug variables.
In all three models, the risk of readmission decreased over time.
The time to readmission was reduced with the number of episodes.
Models 2 and 3 show that the time to readmission was reduced for
the following clinical parameters: recurrent depressive disorder
at the index episode, substance use disorder and more severe ill-
ness. Moreover, we found an interaction effect between personality
disorder and time: although patients with a personality disorder
initially had a longer time to readmission, the time was reduced by
half over time. Employment at the index episode and longer hospi-
tal stays lengthened the time to readmission. Regarding medication
variables in model 3, sertraline (SSRI) was the only significant anti-
depressant reducing the risk of readmission by an odds ratio (OR)
of 0.63 (95% CI= 0.49–0.81) meaning a lengthening of the time
to readmission by 37% (95% CI= 19–51%). Further, we found an
Table 1 | Sample characteristics at time after discharge from index
hospitalization.
Characteristic Total, N (%)
Sociodemography Gender, female 1149 (63.7)
Age 48 (55–40)
Employment, yes 643 (35.7)
Clinical variables,
secondary disorders
Recurrent depressive disorder
(F33) [vs. depressive episode
(F32)]
792 (43.9)
Severity of disorder, severe (vs.
light to moderate)
908 (50.4)
Organic disorder 38 (2.1)
Substance use disorder 346 (19.2)
Psychotic disorder 48 (2.7)
Affective disorder 7 (0.4)
Anxiety disorder 491 (27.2)
Behavioral disorder 66 (3.7)
Personality disorder 371 (20.6)
Admission variables Length of stay 34 (53–18)
Type of admission, emergency 481 (26.7)
Medication, substances NSMRI 106 (5.9)
SSRIa 350 (19.4)
Other 625 (34.7)
Sedatives 138 (7.7)
Psychotropics, others 632 (35.1)
Somatic medication 773 (42.9)
Citalopram/escitalopram (SSRI) 272 (15.1)
Sertraline (SSRI) 86 (4.8)
Trimipramine (NSMRI) 106 (5.9)
Mirtazapine (others) 297 (16.5)
Venlafaxine (others) 293 (16.3)
Duloxetine (others) 106 (5.9)
aN= 8 patients used two different SSRI drugs at the same time (resulting in
N=350 patients and N=358 prescriptions).
interaction effect between sedatives and time: the prescription of
sedatives shortened the time to readmission within 2 years after
index hospitalization. We did not find an indication that sertra-
line had a different effect with respect to severity of the disorder
(results not shown).
GEE MODEL: PREDICTORS OF BEING IN HOSPITAL IN A GIVEN WEEK
According to the procedure described above, we again computed
three statistical models by analyzing probable predictors of the
variable “hospital stay in a given week” (yes: event= 1 vs. no
event= 0) (Table 3). Regarding models 2 and 3, having a recur-
rent depressive disorder at index episode, having a secondary
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Table 2 | Discrete-time hazards model: predictors of time to readmission.
Characteristic Model 1 Model 2 Model 3
OR 95%-CI OR 95%-CI OR 95%-CI
Constant 0.04 0.04–0.05 0.05 0.04–0.06 0.05 0.04–0.07
Time (log) 0.53 0.51–0.56 0.52 0.50–0.55 0.51 0.48–0.54
Number of episodes (log) 2.31 2.14–2.50 1.95 1.78–2.13 1.91 1.74–2.10
Sociodemography
Age – – 1.00 0.99–1.01 1.00 1.00–1.01
Gender, female – – 1.13 1.02–1.25 1.11 0.99–1.23
Employment, yes – – 0.76 0.67–0.85 0.77 0.68–0.86
Clinical variables at index
Secondary disorder, personality – – 0.87 0.67–1.09 0.84 0.66–1.08
Secondary disorder, personality× time (log) 1.15 1.05–1.26 1.16 1.06–1.28
Secondary disorder, substance abuse – – 1.40 1.25–1.57 1.39 1.23–1.57
Severity of disorder at index – – 1.16 1.04–1.30 1.15 1.03–1.28
Main diagnosis, F33 – – 1.20 1.08–1.35 1.20 1.07–1.34
Admission variablesa
LOS (log) – – 0.87 0.84–0.91 0.87 0.83–0.91
Medicationa
Sedatives – – – – 0.94 0.66–1.35
Sedatives× time (log) – – – – 1.32 1.16–1.50
Psychotropics, others – – – – 1.04 0.93–1.16
Somatic medication – – – – 0.92 0.82–1.03
Substancesa
Citalopram/escitalopram (SSRI) – – – – 1.09 0.94–1.27
Sertraline (SSRI) – – – – 0.63 0.49–0.81
Trimipramine (NSMRI) – – – – 1.06 0.86–1.32
Mirtazapine (others) – – – – 0.96 0.84–1.10
Venlafaxine (others) – – – – 1.01 0.87–1.17
Duloxetine (others) – – – – 0.92 0.77–1.10
In total, we considered N=181,049 observations (person–period dataset) with N=1822 events.
aTime-varying covariates.
Log=natural logarithm.
personality or substance disorder, and being more severely ill at
the index episode increased the probability of being in hospital.
Employment status decreased the risk of being in hospital. With
respect to drug variables, using somatic medication or using ser-
traline (SSRI) both reduced the weeks of being in hospital by 40%
(95% CI= 32–48%).
Again, the interaction between sertraline and severity of the
disorder was not significant (results not shown).
DISCUSSION
This study aimed to analyze the relationship between antidepres-
sant substances in outpatient care and time to readmission or
probability of being in hospital by prescription data. We were inter-
ested in treatment under ecological conditions with the respective
clinical and economic implications.
In our study, the antidepressant sertraline was linked with a
lengthened time to readmission and a reduced probability of being
in hospital. Our findings were irrespective of the severity of the dis-
order at the index episode (see above). Due to differences in design
and time span, it is difficult to compare our results with exper-
imental trials. As stated, previous evidence on antidepressants
is contradictory. The observation period of experimental trials
mainly ranges between 6 and up to 24 weeks. However, inter-
estingly, recent reviews on acute-phase treatment particularly
favored sertraline over several new antidepressants in terms of
efficacy, acceptability, and tolerability (14, 15). Another inter-
esting placebo-controlled study showed that the time to relapse
was significantly longer for depressive patients receiving sertra-
line compared to a placebo (31). Further, continuation sertraline
treatment was associated with improved quality of life.
Due to lack of data, it was not possible to account for certain
variables in our study. For example, it remains unclear if patient
adherence has been particularly high in patients using sertraline.
Further, physician preferences, dosage, toxic effects, discontinu-
ation symptoms, pattern of medication use, treatment latency,
social functioning, or quality of life could not be explored.
Only 5% of the patients received sertraline in this study.
Most patients used venlafaxine or mirtazapine. In Germany, ser-
traline and venlafaxine belong to the group of antidepressants
licensed for recurrence prophylaxis in unipolar depression (4).
The prescription pattern in our study is contrary to European
data (10) and studies conducted in the US (1, 2, 30, 32), reporting
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Table 3 | GEE model: predictors of being in hospital in a given week.
Characteristic Model 1 Model 2 Model 3
OR 95%-CI OR 95%-CI OR 95%-CI
Constant 0.06 0.04–0.07 0.03 0.02–0.04 0.02 0.02–0.04
Time (log) 2.24 1.53–3.27 2.26 1.54–3.31 2.30 1.56–3.39
Time (log)× time (log) 0.72 0.59–0.86 0.71 0.59–0.86 0.71 0.59–0.86
Time (log)× time (log)× time (log) 1.03 1.01–1.06 1.03 1.01–1.06 1.03 1.01–1.06
Sociodemography
Age – – 1.01 1.00–1.01 1.01 1.01–1.02
Gender, female – – 1.22 1.02–1.46 1.27 1.07–1.52
Employment, yes – – 0.68 0.56–0.83 0.65 0.54–0.79
Clinical variables at index
Secondary disorder, personality – – 1.36 1.11–1.66 1.38 1.13–1.68
Secondary disorder, substance abuse – – 1.52 1.25–1.85 1.52 1.26–1.85
Severity of disorder at index – – 1.29 1.09–1.54 1.29 1.09–1.53
Main diagnosis, F33 – – 1.32 1.11–1.58 1.38 1.16–1.64
Medicationa
Sedatives – – – – 1.10 0.91–1.34
Psychotropics, others – – – – 0.92 0.81–1.04
Somatic medication – – – – 0.60 0.52–0.68
Substancesa
Citalopram/escitalopram (SSRI) – – – – 0.97 0.78–1.20
Sertraline (SSRI) – – – – 0.60 0.42–0.86
Trimipramine (NSMRI) – – – – 0.81 0.60–1.09
Mirtazapine (others) – – – – 0.91 0.76–1.09
Venlafaxine (others) – – – – 0.90 0.74–1.09
Duloxetine (others) – – – – 0.92 0.72–1.18
We considered N=189,315 observations (person–period dataset) with N=10,088 events.
aTime-varying covariates.
Log=natural logarithm.
that SSRIs were most frequently prescribed. Further, at least in the
US, sertraline is the most prescribed single agent (1). It remains
unclear why sertraline was so rarely prescribed in our sample. One
explanation might be undertreatment (see below). Further, the use
of SSRIs might imply health-related disadvantages, even if sertra-
line appears to be well tolerated. Common side effects of SSRIs
are sexual dysfunction in men, CNS, and anticholinergic effects as
well as gastrointestinal distress (3). The association between SSRIs
and cancer or suicidality has yet to be proven (33–35).
As mentioned above, antidepressants other than sertraline
were not significantly related to our outcome variables. Accord-
ingly, the usefulness of antidepressants could be viewed critically,
as argued by other authors (36). Further, about 50% of the
patients in our study did not receive any antidepressant relevant
for our study in the week after discharge from index hospital-
ization. This corresponds to findings on depressive outpatients
with up to more than half not receiving depression-specific treat-
ment (37–39). Those numbers of patients with antidepressant
treatment are unexpectedly low, at least when compared to stud-
ies on depressive inpatients (12). The role of factors such as
utilization of prescription-free herbal antidepressants not regis-
tered in our prescription database or non-compliance to pre-
scribed antidepressants remains unclear. At least the first is
unlikely because patients without prescribed antidepressants did
not differ from patients with antidepressants with respect to
severity of illness (results not shown). Further, lack of data qual-
ity could have played a role: lack of information on dispersion
of antidepressant medication during inpatient treatment might
imply that some patients continued using medication delivered
to them in the hospital (see limitations below). When consider-
ing several antidepressant substances not included in our study
due to their small prevalence (≈<5%), the number of patients
using antidepressant medication at baseline increased to only
58%. Besides sertraline, sedatives and somatic medication were
significant in our study. Sedatives, used by about 8% of the
patients, appeared to increasingly reduce the time to readmis-
sion over the study period (Table 2). The use of sedatives seems
to be more pronounced in patients with readmissions and is
probably related to the acute-phase of mental illness. Possibly,
misuse or dependency played a role. The German guidelines
recommend sedatives as a short-term treatment to overcome
the treatment latency of the antidepressant effect and acute
agitation (4).
Concerning somatic medication, we found a reduction of the
risk of being in hospital. The use of somatic medication might
serve as an indicator for the predominance of somatic compared to
psychiatric symptoms, probably also affecting treatment-seeking
behavior.
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We controlled for time and the episode-specific variables as
number of previous inpatient episodes and length of stay. Our
finding of a decreasing risk of readmission over time after index
hospitalization corresponds with another study on schizophrenic
patients (40). In line with previous studies (24, 26, 41), we have
found that a higher number of previous psychiatric admissions
reduces the time to readmission. This might be related to a
treatment-seeking behavior (26) and/or the vulnerability to fur-
ther crisis and hospitalizations (41). Regarding length of stay,
shorter previous hospital stay was associated with a reduced
time to readmission. It remains unclear whether this refers to
the revolving-door phenomenon and if patients were previously
discharged too early. In a study on unipolar depression, a first
hospitalization of between 15 and 30 days was associated with the
shortest mean cumulative length of stay (42).
Further relevant predictor variables in our study were employ-
ment status, severity of illness, diagnosis, and secondary diagnosis.
Employment at index hospitalization had a preventive effect on the
outcomes. Accordingly, previous studies showed a link between
employment and a lower risk of hospital readmission (43–45). In
particular, employed mentally ill patients seem to prefer psychi-
atric outpatient compared to inpatient treatment (45), probably
to ensure keeping their job. Illness-related variables were associ-
ated with a shorter time to readmission and a higher probability
of being in hospital. Previous studies on time to readmission cor-
respond with these results (24). In general, studies on psychiatric
inpatient length of stay suggest that treatment and organizational
variables have a higher impact than patient variables (46).
The limitations of this study are the following: our study was
not an experimental trial, which is a strength and a weakness at
the same time. On the one hand, our data have higher ecological
validity considering that the choice of pharmacotherapy is driven
primarily by patient choice (9). On the other, only experimen-
tal trials allow for direct causal conclusions (47). In our dataset,
important variables were missing (see above), e.g., medication
prescription during hospitalization, compliance, toxicity of the
antidepressant drugs, or quality of life. An examination of the lat-
ter outcome criteria could give further insight into the value or
utility of the respective antidepressants. Concerning medication
prescription during hospitalization, the same drugs were equally
distributed during the time in and out of hospital (results not
shown). Data like illness severity or employment were considered
only for the time of the index admission. This was because we
were interested in baseline patient characteristics. The validity of
the dataset remains unclear, but we aimed to improve data quality
by sample selection. Further, we compared patients with different
severity levels and treatment histories. However, for this analysis
we were interested in all depressive patients. A reanalysis of our
research question with a larger sample and a higher number of
patients receiving sertraline might be promising.
In summary, this study analyzed antidepressants as possible
predictors of the time to readmission and the probability of being
in hospital in a given time period. Sertraline was the only sub-
stance with a preventive effect concerning time to readmission
and probability of being in hospital. Its prescription might have
positive clinical and economic consequences. However, this sub-
stance was prescribed only to a minority of patients, which is
contrary to the prescribing pattern in the US. Future research on
further outcome parameters like toxic effects of antidepressants
and quality of life is necessary to comprehensively assess the utility
of antidepressant drugs.
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